Autonomix Secures U.S. Patent For Precision Nerve-Mapping And RF Ablation Technology

Autonomix Medical, Inc., a medical device company focused on precision nerve-targeted therapies, announced the issuance of U.S. Patent No. 12,257,071 by the U.S. Patent and Trademark Office. The patent, titled Controlled sympathectomy and micro-ablation systems and methods, protects Autonomix’s proprietary catheter-based system that integrates nerve mapping and RF ablation, offering a minimally invasive solution to treat nerve-related conditions.

“We are excited to announce the issuance of this patent, marking a key milestone in our strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation. This innovative technology enhances our intellectual property position in the rapidly growing nerve-focused therapeutics space, allowing us to protect our offerings and deliver improved solutions for both clinicians and patients. This patent is a vital addition to our expanding portfolio as we continue working toward our goal of revolutionising the treatment of nerve-related conditions,” commented Brad Hauser, CEO of Autonomix.

Key elements of the patent are microfingers that can expand into various positions, real-time monitoring, and the ability to manage, map, stimulate, ablate, and measure nerve functions through a single integrated tool. The technology is able to use EMG, MMG, or bioimpedance information to help with changing modulation, and may be useful for hypertension, chronic pain, and disorders related to the sympathetic nerves or metabolism.

Autonomix's system represents a significant leap over conventional treatments, which often involve opioids or invasive procedures. The company’s proprietary RF ablation platform offers a more precise and potentially safer option. Looking ahead, Autonomix plans to submit an Investigational Device Exemption (IDE) in 2025 to begin U.S. clinical trials, starting with an indication for pancreatic cancer-related pain.